Scholarly Index
Meredith M. Regan
Dana-Farber Cancer Institute; 40,507 total citations; 513 total publications; best world rank #80
Dana-Farber Cancer Institute
40,507Total citations
513Total publications
92H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Breast Cancer Treatment Studies | Lifetime | 118 | US 65 | 99.59 |
| Estrogen and related hormone effects | Lifetime | 145 | US 99 | 99.31 |
| Advanced Breast Cancer Therapies | Lifetime | 80 | US 41 | 99.28 |
| HER2/EGFR in Cancer Research | Lifetime | 371 | US 176 | 98.39 |
| Renal cell carcinoma treatment | Lifetime | 429 | US 234 | 98.09 |
| Prostate Cancer Treatment and Research | Lifetime | 852 | US 455 | 97.69 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 955 | US 454 | 97.17 |
| Statistical Methods in Clinical Trials | Lifetime | 524 | US 277 | 94.48 |
| Breast Cancer Treatment Studies | 2021-2025 | 89 | US 34 | 98.76 |
| Advanced Breast Cancer Therapies | 2021-2025 | 141 | US 51 | 97.69 |
| Estrogen and related hormone effects | 2021-2025 | 85 | US 37 | 93.53 |
| Cancer Genomics and Diagnostics | 2021-2025 | 899 | US 383 | 94.82 |
| HER2/EGFR in Cancer Research | 2021-2025 | 915 | US 301 | 85.72 |